Cargando…
Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners
Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable response rates and revolutionized the treatment of patients suffering from defined hematological malignancies. However, many patients still do not respond to this therapy or relapse after an initial remission, underscoring the ne...
Autores principales: | Stock, Sophia, Kluever, Anna-Kristina, Endres, Stefan, Kobold, Sebastian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869718/ https://www.ncbi.nlm.nih.gov/pubmed/35203517 http://dx.doi.org/10.3390/biomedicines10020307 |
Ejemplares similares
-
Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors
por: Stock, Sophia, et al.
Publicado: (2022) -
Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy
por: Stoiber, Stefan, et al.
Publicado: (2019) -
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
por: Benmebarek, Mohamed-Reda, et al.
Publicado: (2019) -
Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells
por: Darowski, Diana, et al.
Publicado: (2019) -
Chimeric Antigen Receptor–Modified T Cells and T Cell–Engaging Bispecific Antibodies: Different Tools for the Same Job
por: Schwerdtfeger, Melanie, et al.
Publicado: (2021)